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Marinopyrrole A, a marine natural product originally developed for its activity against Methicillin-resistant Staphylococcus aureus, 2, 3 was recently reported by Doi et al. 4 to be a selective
Mcl-1 antagonist that binds to Mcl-1 and targets it for degradation. This publication was received with great interest because the discovery of a specific Mcl-1 inhibitor had thus far eluded researchers. Indeed, the only agents reported to target Mcl-1 to date are general transcription inhibitors, which show limited selectivity for Mcl-1 due to its short half-life. 5, 6 However, previous studies in human colon carcinoma cells reported actin Cell extraction, immunoblotting, and cell viability assays using MTT dye were performed as described previously. 9 Antibodies against Bcl-2 (sc-509) and Mcl-1 (sc-819) were from Santa Cruz (Santa Cruz, CA) and antibodies against Bcl-xL (2762) and GAPDH (14C10) were from Cell Signaling (Beverly, MA) as the primary target of marinopyrrrole A. 2 This raised the possibility that Mcl-1 may not be the primary target for marinopyrrole A in cancer cells. We therefore sought to determine whether marinopyrrole A was indeed a bona fidespecific Mcl-1 inhibitor.
Our recent studies testing the viability of HeLa cells after systematic knockdown of individual anti-apoptotic Bcl-2 proteins demonstrated strict dependence on Mcl-1 (Eichhorn et al., manuscript submitted). We first compared the sensitivity to marinopyrrole of Mcl-1-dependent HeLa cells versus RS4;11 human leukemia cells which have previously been shown to be dependent on Bcl-2 for survival. We next tested whether natural marinopyrrole A would show selective cytotoxicity against Mcl-1-versus Bcl-2-dependent leukemia cell lines as reported by Doi et al. 4 For this purpose we chose two murine leukemia cell lines generated from transgenic mice and established via multiple criteria to be either dependent on Mcl-1 or Bcl-2. 8 Marinopyrrole A was equally effective against Mcl-1-dependent leukemia cells (IC 50 : 2.5 mM) as Bcl-2-dependent cells (IC 50 : 2 mM; Figure 1b) .
It is important to note that data presented by Doi et al. 4 utilized a racemic mixture of synthetic marinopyrrole A, whereas our data and previous work done by Hughes et al. 2 were performed using the natural M-(-)-enantiomer. Therefore, cell viability assays were conducted in the Mcl-1-and Bcl-2-dependent leukemia cell lines using the non-natural P-( þ )-enantiomer, and no statistical difference between the two enantiomers was observed (results not shown).
Finally, we tested whether overexpression of Bcl-2, Bcl-xL, or Mcl-1 would protect HeLa cells from marinopyrrole A. HeLa cells stably overexpressing Bcl-2, Bcl-xL, or Mcl-1 were treated with marinopyrrole A for 72 h and cell viability was assessed. Strikingly, overexpression of each anti-apoptotic Bcl-2 family member conferred complete resistance to marinopyrrole A (Figure 1c) . Thus, marinopyrrole A failed to show selective cytotoxicity towards cells overexpressing Mcl-1 in contrast to previously reported data. 4 The data in Figure 1c indicate that the death signals generated from marinopyrrole A activate the intrinsic apoptotic pathway.
The results reported here are in stark contrast to previously reported data showing that marinopyrrole A induces cell death selectively in Mcl-1-dependent but not Bcl-2-dependent cells. 4 While further studies are needed to establish the basis of this discrepancy, taken together, our results seriously question the validity of marinopyrrole A as a specific Mcl-1 inhibitor.
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